Sugi Predict

Sugi Predict / Targets / SLC2A4

SLC2A4

Solute carrier family 2, facilitated glucose transporter member 4 · P14672 · SLC2A4 on Sugi Atlas →

6,041 patent compounds predicted against SLC2A4, 3,459 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL798557 SCHEMBL798557 0.37 17/20
SCHEMBL686720 SCHEMBL686720 0.35 17/20
SCHEMBL798149 SCHEMBL798149 0.36 15/20
SCHEMBL10118295 SCHEMBL10118295 0.36 15/20
SCHEMBL1218593 SCHEMBL1218593 0.46 14/20
SCHEMBL10118299 SCHEMBL10118299 0.37 14/20
SCHEMBL960289 SCHEMBL960289 0.42 13/20
SCHEMBL2623667 SCHEMBL2623667 0.34 11/20
SCHEMBL2134984 SCHEMBL2134984 0.34 10/20
SCHEMBL685550 SCHEMBL685550 0.36 9/20
SCHEMBL10083626 SCHEMBL10083626 0.34 9/20
SCHEMBL10136602 SCHEMBL10136602 0.34 9/20
SCHEMBL10118297 SCHEMBL10118297 0.35 7/20
SCHEMBL961226 SCHEMBL961226 0.38 6/20
SCHEMBL959387 SCHEMBL959387 0.37 6/20
SCHEMBL3063670 SCHEMBL3063670 0.46 5/20
SCHEMBL962070 SCHEMBL962070 0.43 5/20
SCHEMBL10136318 SCHEMBL10136318 0.35 5/20
SCHEMBL685546 SCHEMBL685546 0.35 5/20
SCHEMBL10075291 SCHEMBL10075291 0.34 5/20

Clinical trials — most relevant to SLC2A4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation. PHASE4COMPLETED
Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration PHASE4COMPLETED
Effect of Anti-diabetic Drugs on Glycemic Variability PHASE4COMPLETED
Dapagliflozin Effect on Erythropoiesis and Physical Fitness PHASE4WITHDRAWN
Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes PHASE4COMPLETED
The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients PHASE4COMPLETED
Reformulated F75 Milk to Treat Severe Acute Malnutrition PHASE2/PHASE3COMPLETED
Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin PHASE2NOT_YET_RECRUITING
Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes PHASE2COMPLETED
PK and PD of YG1699 in CKD Patients With Diabetes PHASE1NOT_YET_RECRUITING
Multi-Tracer PET Assessment of Primary Brain Tumors PHASE1COMPLETED
Sodium Lactate Infusion in GLUT1DS Patients EARLY_PHASE1COMPLETED
A Proof-of-concept Study Evaluating the Microbiota-gut-brain Axis nanRECRUITING
Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients nanCOMPLETED
Clinical Utility of Breath Tests in GI nanCOMPLETED
Red Blood Cell Exchange Transfusion as a Novel Treatment for GLUT1 Deficiency Syndrome nanSUSPENDED
The Effect of Green Coffee Extract on Blood Glucose Homeostasis in Healthy Adults nanCOMPLETED
RESIST! Blood-flow Restriction Resistance Training for Improving Insulin Sensitivity in Type 2 Diabetes nanUNKNOWN
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
Characterization of Abdomino-pelvic Lesions by 18Fluorine- Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography nanNOT_YET_RECRUITING
Impact of Sodium Glucose Co-transporter 2-Inhibitors on Clinical Outcome and Left Ventricular Function in Patients Presented by Acute Myocardial Infarction nanCOMPLETED
Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer nanUNKNOWN
SLC2A1 Variants and Diabetic Nephropathy nanCOMPLETED
Insulin Resistance in Relation to Hyperthyroidism and Hypothyroidism nanUNKNOWN
Multi-Tracer PET Quantitation of Skeletal Muscle Insulin Resistance in Type 2 Diabetes Mellitus nanCOMPLETED
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients. nanRECRUITING
The Effect of Artificial Sweeteners on Blood Glucose Response nanWITHDRAWN
Glutamate Supplementation in Young Men nanCOMPLETED
Genetic Variation in CLTCL1 and Whole-body Glucose Control nanCOMPLETED
Hepatic Substrate Flux Rates in Type 2 Diabetes nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a SLC2A4 binder may also engage these)

ProteinNameSimilarity
Q27994 — 1.000 Q27994 →
P19357 — 0.998 P19357 →
P14142 — 0.994 P14142 →
P79365 — 0.988 P79365 →
P13355 — 0.983 P13355 →
O62787 — 0.983 O62787 →
P27674 — 0.983 P27674 →
P17809 — 0.982 P17809 →
P11167 — 0.981 P11167 →
A4ZYQ5 — 0.981 A4ZYQ5 →
Q90592 — 0.980 Q90592 →
P20303 — 0.980 P20303 →
P12336 — 0.980 P12336 →
P46896 — 0.979 P46896 →
SLC2A1 Solute carrier family 2, facilitated glucose transporter member 1 0.979 landscape →
Q6PXP3 — 0.978 Q6PXP3 →
P47843 — 0.977 P47843 →
SLC2A3 Solute carrier family 2, facilitated glucose transporter member 3 0.975 landscape →
Q07647 — 0.975 Q07647 →
Q5R608 — 0.975 Q5R608 →
P0C6A1 — 0.974 P0C6A1 →
P58352 — 0.974 P58352 →
Q9XSC2 — 0.973 Q9XSC2 →
Q863Y9 — 0.973 Q863Y9 →
P14246 — 0.972 P14246 →
P22732 — 0.972 P22732 →
P47842 — 0.972 P47842 →
Q8TDB8 — 0.971 Q8TDB8 →
P28568 — 0.969 P28568 →
Q5RET7 — 0.969 Q5RET7 →